LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF

NCT05983250 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

230

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Hypertension

Interventions

DRUG: TNX-103
DRUG: Placebo

Sponsor

Tenax Therapeutics, Inc.

Collaborators

[object Object]
[object Object]